Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Authors: Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD

Source: JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)

Subject Terms: Non–small cell lung cancer, Avelumab, Lorlatinib, Crizotinib, Phase 1b/2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000559; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/50d39c846b474baea88547c6b345e6aa

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Authors: Sviatoslav Chekhun, Assumpció Lopez-Paradís, Aintzane Urbizu, Teresa Morán, Anabel Mañes, Marc Cucurull, Carlos Martínez-Barenys, Iris Teruel, Gloria Moragas, Enric Carcereny, Ana Maria Muñoz Mármol, Maria Saigí

Source: Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1182-1187 (2023)

Subject Terms: lung adenocarcinoma, epidermal growth factor receptor, oligoprogression, targeted therapy, epidermal growth factor receptor-tyrosine kinase inhibitors, Internal medicine, RC31-1245

File Description: electronic resource

Relation: https://www.explorationpub.com/Journals/etat/Article/1002191; https://doaj.org/toc/2692-3114

Access URL: https://doaj.org/article/548b16587d6e4b5780c5798654aef425

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

Authors: Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip

Source: Molecular Oncology, Vol 17, Iss 5, Pp 779-791 (2023)

Subject Terms: aneuploidy, cfDNA, immune checkpoint inhibitors, liquid biopsy, NSCLC, shallow whole‐genome sequencing, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261

Access URL: https://doaj.org/article/604e6cdc2d234a06b5347b1a01ff2632

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Authors: Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, Mariano Provencio

Source: ERJ Open Research, Vol 9, Iss 6 (2023)

Subject Terms: Medicine

File Description: electronic resource

Relation: http://openres.ersjournals.com/content/9/6/00468-2023.full; https://doaj.org/toc/2312-0541

Access URL: https://doaj.org/article/a612acb88ba047f79e4cc339b0b86a9c

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Authors: Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/6b475fde214d41829d313ffd4989b729

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Authors: Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes, Marta Costa, Jose-Luis Mate, Anna Esteve, Maria Saigí

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: non-small cell lung cancer, lung adenocarcinoma, KRAS, PD-L1, immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1239000/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/6460f628e9154bd29ea1ff2e9b47c256

Representatividad del Registro de Tumores Torácicos de España. Comparación de datos sociodemográficos con otros registros nacionales

Authors: Cristina Candal-Pedreira, Alberto Ruano-Ravina, Enric Carcereny, Delvys Rodríguez-Abreu, María Guirado-Risueño, Rafael López-Castro, Bartomeu Massutí, Ana Blasco, Ana Laura Ortega, Mariano Provencio

Source: Gaceta Sanitaria, Vol 36, Iss 6, Pp 540-545 (2022)

Subject Terms: Lung cancer, Spain, Cancer registry, Sex, Age, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0213911122001017; https://doaj.org/toc/0213-9111

Access URL: https://doaj.org/article/fd9dc90f3fc144bb8b00a0e6de49dc00

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Authors: Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente

Source: BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)

Subject Terms: Biomarkers, Testing, Metastatic lung cancer, Targeted therapies, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/0111fe9f31fa49208eab155d42059c73

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Authors: Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio

Source: BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

Subject Terms: Non-small cell lung cancer, EGFR, Predictive modeling, Nomogram, Long survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/233d05bfad794aa8b762c296fe046b5c

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Authors: Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell

Source: Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/907f95952a6f451dab4695071025b8b3

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Authors: Marc Cucurull, Lucia Notario, Montse Sanchez-Cespedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí

Source: Frontiers in Oncology, Vol 11 (2022)

Subject Terms: KRAS, NSCLC, ICI, PD-L1, STK11, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.793121/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/ffbe2d7461754e19b5b912b54bef0fbb

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

Authors: James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD

Source: JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100114- (2021)

Subject Terms: EGFR tyrosine kinase inhibitor, Epidermal growth factor receptor mutations, Non–small cell lung cancer, Phase III randomized clinical trial, Rociletinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364320301600; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/3960fcdf0ad54bcf8d21572f501bc5e5

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.

Authors: Fernando Franco, Enric Carcereny, Maria Guirado, Ana L Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel Del Barco, Oscar Juan, Francisco Aparisi, Jose L González-Larriba, Manuel Domine, Jose M Trigo, Manuel Cobo, Sara Cerezo, Julia Calzas, Bartomeu Massutí, Joaquim Bosch-Barrera, Paola García Coves, Marta Domènech, Mariano Provencio

Source: PLoS ONE, Vol 16, Iss 6, p e0251761 (2021)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/1932-6203

Access URL: https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Authors: Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Leora Horn, Frederic Triebel, Enric Carcereny, Margarita Majem, Bernard Doger, Julio Peguero, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone

Source: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/d02a1f2a6b8e4e9da090b71bfd077dab

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Authors: Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., Peters, S.

Source: In Annals of Oncology January 2024 35(1):66-76

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib

Authors: Moran, Teresa, Palmero, Ramón, Provencio, Mariano, Insa, Amelia, Majem, Margarita, Reguart, Noemí, Bosch-Barrera, Joaquim, Isla, Dolores, Costa, Enric Carcereny, Lee, Chooi, Puig, Marta, Kraemer, Sandrine, Schnell, David, Rosell, Rafael

Source: In Lung Cancer June 2017 108:154-160

PP01.104 Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases

Authors: Awad, Mark M., Devarakonda, Siddhartha, Yang, Jin-Li, Zhang, Yan, Wu, Lin, Hu, Jie, Wang, Zhe-Hai, Chen, Jing-Hua, Fan, Yun, Zhao, Jun, Fang, Jian, Song, Yong, Li, Xing-Ya, Perol, Maurice, Planchard, David, Garrido, Pilar, Lindsay, Colin, Moore, Melissa M., Bulotta, Alessandra, Costa, Enric Carcereny, Provencio, Mariano, Chih-Hsin Yang, James, Spigel, David, Nadal, Ernest, Peony Yu, Kin-Hung, Wu, Yi-Long

Source: Journal of Thoracic Oncology; July 2024, Vol. 19 Issue: 7, Number 7 Supplement 1 pe45-e46, 2p

This result is not displayed to guests.
Login for full access.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors: Hellmann, Matthew D.¹, hellmanm@mskcc.org, Paz-Ares, Luis², Caro, Reyes Bemabe³, Zurawski, Bogdan⁴, Sang-We Kim⁵, Costa, Enric Carcereny⁶, Keunchil Park⁷, Alexandra, Aurelia⁸, Lupinacci, Lorena⁹, la Mora Jimenez, Emmanuel de¹⁰, Sakai, Hiroshi¹¹, Albert, Istvan¹², Vergnenegre, Alain¹³, Peters, Solange¹⁴, Syrigos, Konstantinos¹⁵, Barlesi, Fabrice¹⁶, Reck, Martin¹⁷, Borghaei, Hossein¹⁸, Brahmer, Julie R.¹⁹, O’Byrne, Kenneth J.²⁰

Source: New England Journal of Medicine; 11/21/2019, Vol. 381 Issue 21, p2020-2031, 12p

This result is not displayed to guests.
Login for full access.